MorphoSys Recognized as Technology Pioneer 2009 by the World Economic Forum
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the Company has been recognized by the World Economic Forum as a Technology Pioneer 2009. The World Economic Forum has selected 34 companies out of more than 320 applications from 15 countries for their accomplishments as innovators, and their work’s current and future impact on business and society.
The Technology Pioneers program of the Forum aims to recognize companies that have contributed to the Forum’s mission of improving the state of the world and are at the forefront of technology and innovation. To be selected as a Technology Pioneer, a company must be involved in the development of life-changing technology innovation and have the potential for long-term impact on business and society. In addition, it must demonstrate visionary leadership and show all the signs of being a long-standing market leader - and its technology must be proven.
“We congratulate the 34 newly selected Technology Pioneers for their remarkable achievements and welcome them to the wider community of the World Economic Forum. During these difficult times, we are certain that the technologies driven by these visionary companies will contribute to the next wave of growth, with the innovative and entrepreneurial spirit that characterizes them,” said André Schneider, Managing Director and Chief Operating Officer of the World Economic Forum.
For more information please visit the official website of the World Economic Forum:
MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys’s goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The Company currently has therapeutic and research alliances with the majority of the world’s largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford). For further information please visit http://www.morphosys.com/
HuCAL®, HuCAL GOLD®, RapMAT® and HuCAL PLATINUM® are registered trademarks of MorphoSys AG
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company’s assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.